Abstract
Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2969-2975 |
| Number of pages | 7 |
| Journal | Supportive Care in Cancer |
| Volume | 20 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2012 |
Fingerprint
Keywords
- Autologous hematopoietic progenitor cell transplantation
- Multiple myeloma
- Osteonecrosis of the jaw
ASJC Scopus subject areas
- Oncology
Cite this
Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw : A longitudinal cohort study. / Varadarajan, Prakash; Toro, Juan J.; Lee, Shuko; Schneider, Deanna; Neumon, Bonita; Frye, Brenda; Craig, Robert M.; Haile, David J.; Freytes, César O.
In: Supportive Care in Cancer, Vol. 20, No. 11, 11.2012, p. 2969-2975.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw
T2 - A longitudinal cohort study
AU - Varadarajan, Prakash
AU - Toro, Juan J.
AU - Lee, Shuko
AU - Schneider, Deanna
AU - Neumon, Bonita
AU - Frye, Brenda
AU - Craig, Robert M.
AU - Haile, David J.
AU - Freytes, César O.
PY - 2012/11
Y1 - 2012/11
N2 - Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.
AB - Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.
KW - Autologous hematopoietic progenitor cell transplantation
KW - Multiple myeloma
KW - Osteonecrosis of the jaw
UR - http://www.scopus.com/inward/record.url?scp=84868458091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868458091&partnerID=8YFLogxK
U2 - 10.1007/s00520-012-1429-4
DO - 10.1007/s00520-012-1429-4
M3 - Article
C2 - 22418599
AN - SCOPUS:84868458091
VL - 20
SP - 2969
EP - 2975
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 11
ER -